Generic Name and Formulations:
Tropicamide 0.5%, 1%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for MYDRIACYL:
For mydriasis and cycloplegia for diagnostic procedures.
Adults and Children:
For refraction: instill 1–2 drops of 1% soln in the eye(s); repeated in 5 minutes. An additional drop may be instilled if patient is not seen within 20–30 minutes. For examination of fundus: instill 1–2 drops of 0.5% soln 15 or 20 minutes prior to exam. Lacrimal sac should be compressed by digital pressure for 2–3 minutes after instillation to reduce excessive systemic absorption.
Remove contact lenses before use. Pregnancy (Cat.C). Nursing mothers.
May interfere with antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Ocular (eg, stinging, blurred vision, photophobia, superficial punctuate keratitis, transient elevation of intraocular pressure), dry mouth, tachycardia, headache, allergic reactions, GI upset, pallor, CNS disturbances (esp. in children).
Soln 0.5%—15mL; 1%—3mL, 15mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|